New Phase 2 Trials to Evaluate Filgotinib in Two Types of Crohn’s Disease

New Phase 2 Trials to Evaluate Filgotinib in Two Types of Crohn’s Disease
Galapagos NV, collaborating with Gilead Sciences, will soon begin recruiting for  announced two new Phase 2 clinical trials to evaluate filgotinib in patients with small bowel Crohn’s disease, as well as in patients with fistulizing Crohn’s disease. Galapagos and Gilead Sciences have a global partnership for the development and commercialization of filgotinib for inflammatory diseases. Filgotinib is

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

Leave a Comment

Your email address will not be published. Required fields are marked *